$672 Million is the total value of Aisling Capital LLC's 18 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ESPR | Sell | ESPERION THERAPEUTICS INC. | $133,851,000 | -29.6% | 1,637,125 | -20.3% | 19.93% | -19.9% |
| ZLTQ | Buy | ZELTIQ AESTHETICS INC | $76,702,000 | -4.2% | 2,602,738 | +0.2% | 11.42% | +9.0% |
| CEMP | Sell | CEMPRA INC | $75,354,000 | -33.3% | 2,193,060 | -33.4% | 11.22% | -24.1% |
| LOXO | LOXO ONCOLOGY INC | $62,248,000 | +44.8% | 3,452,493 | 0.0% | 9.27% | +64.8% | |
| CMRX | CHIMERIX INC. | $47,260,000 | +22.6% | 1,022,943 | 0.0% | 7.04% | +39.5% | |
| TTOO | T2 BIOSYSTEMS INC | $40,953,000 | +4.6% | 2,523,300 | 0.0% | 6.10% | +19.0% | |
| VSAR | VERSARTIS INC | $34,695,000 | -17.1% | 2,279,568 | 0.0% | 5.17% | -5.7% | |
| ADMA | ADMA BIOLOGICS INC | $33,412,000 | -5.5% | 3,608,171 | 0.0% | 4.98% | +7.5% | |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $30,022,000 | +47.3% | 1,703,855 | -3.4% | 4.47% | +67.6% |
| AGRX | AGILE THERAPEUTICS INC | $25,631,000 | -7.3% | 2,983,797 | 0.0% | 3.82% | +5.4% | |
| TRXC | TRANSENTERIX INC. | $25,007,000 | +2.4% | 8,335,819 | 0.0% | 3.72% | +16.5% | |
| CTLT | Sell | CATALENT INC | $20,991,000 | -39.1% | 715,673 | -35.3% | 3.13% | -30.7% |
| DERM | DERMIRA INC | $19,341,000 | +14.3% | 1,102,046 | 0.0% | 2.88% | +30.1% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $17,593,000 | -17.6% | 682,680 | 0.0% | 2.62% | -6.2% | |
| PTX | PERNIX THERAPEUTICS HLDGS IN | $11,899,000 | -44.6% | 2,010,000 | 0.0% | 1.77% | -37.0% | |
| XENT | INTERSECT ENT INC | $10,021,000 | +10.8% | 350,000 | 0.0% | 1.49% | +26.1% | |
| EVAR | LOMBARD MED INC | $3,900,000 | +9.2% | 886,363 | 0.0% | 0.58% | +24.4% | |
| ROKA | Sell | ROKA BIOSCIENCE INC | $2,677,000 | -25.5% | 1,029,693 | -8.3% | 0.40% | -15.1% |
| MEIP | Exit | MEI PHARMA INC | $0 | – | 0 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.